Pregnancy-induced chromatin remodeling in the breast of postmenopausal women. by Russo, J. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Pregnancy-induced chromatin remodeling in the breast of 
postmenopausal women. 
Authors: Russo J, Santucci-Pereira J, de Cicco RL, Sheriff F, Russo PA, 
Peri S, Slifker M, Ross E, Mello ML, Vidal BC, Belitskaya-Lévy I, Arslan 
A, Zeleniuch-Jacquotte A, Bordas P, Lenner P, Ahman J, Afanasyeva Y, 
Hallmans G, Toniolo P, Russo IH 
Journal: International journal of cancer 
Year: 2012 Sep 1 
Volume: 131 
Issue: 5 
Pages: 1059-70 
DOI: 10.1002/ijc.27323 
 
Pregnancy-induced chromatin remodeling in the breast of
postmenopausal women
Jose Russo1,11, Julia Santucci-Pereira1, Ricardo López de Cicco1, Fathima Sheriff1,
Patricia A. Russo1, Suraj Peri2, Michael Slifker2, Eric Ross2, Maria Luiza S. Mello3,
Benedicto C. Vidal3, Ilana Belitskaya-Lévy4, Alan Arslan5,9, Anne Zeleniuch-Jacquotte5, Pal
Bordas6, Per Lenner7, Janet Ahman6, Yelena Afanasyeva5, Goran Hallmans8, Paolo
Toniolo5,9,10, and Irma H. Russo1
1Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
2Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA,
19111, USA 3Institute of Biology, University of Campinas, Campinas, SP, Brazil 4Division of
Biostatistics, Department of Environmental Medicine, New York University School of Medicine,
New York, NY, 10016, USA 5Division of Epidemiology, Department of Environmental Medicine,
New York University School of Medicine, New York, NY, 10016, USA 6Sunderby Hospital, Luleå
and the Norrbotten Mammography Screening Program, Luleå, Sweden 7Departments of
Radiation Sciences and Oncology, Umeå University, Umeå, Sweden 8Department of Public
Health and Clinical Medicine, Umeå University, Umeå, Sweden 9Department of Obstetrics and
Gynecology, New York University School of Medicine, New York, NY, 10016, USA 10Institute of
Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Abstract
Early pregnancy and multiparity are known to reduce the risk of women to develop breast cancer
at menopause. The knowledge that the differentiation of the breast induced by the hormones of
pregnancy plays a major role in this protection, the present work was performed with the purpose
of identifying what differentiation-associated molecular changes persist in the breast until
menopause. Core needle biopsies (CNB) obtained from the breast of 42 nulliparous (NP) and 71
parous (P) postmenopausal women were analyzed in morphology, immunocytochemistry and gene
expression. Whereas in the NP breast nuclei of epithelial cells were large and euchromatic, in the
P breast they were small and hypercromatic, showing strong methylation of istone 3 at lysine 9
and 27. Transcriptomic analysis performed using Affymetrix HG_U133 oligonucleotide arrays
revealed that in CNB of the P breast there were 267 upregulated probesets that comprised genes
controlling chromatin organization, transcription regulation, splicing machinery, mRNA
processing, and noncoding elements including XIST. We concluded that the differentiation
process induced by pregnancy is centered in chromatin remodeling and in the mRNA processing
reactome, both of which emerge as important regulatory pathways. These are indicative of a
safeguard step that maintains the fidelity of the transcription process, becoming the ultimate
mechanism mediating the protection of the breast conferred by full term pregnancy.
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Introduction
Breast cancer is the most frequently diagnosed cancer in postmenopausal women and the
leading cause of cancer death in females worldwide 1. The global incidence of breast cancer
has gradually increased over the last few decades 1, 2. Although the reasons of this increase
are uncertain, it is known that the breast cancer risk is reduced in women who gave birth to a
child before age 24 3, a reduction that is enhanced by breast feeding and multiparity 4, 5.
Experimentally it has been demonstrated that the protection conferred by pregnancy is
mediated by the differentiation of the breast, a physiological process driven by the complex
hormonal milieu created by the placenta and the fetus 6–8. The postulate that the degree of
differentiation acquired through an early pregnancy changes the genomic signature that
differentiates the lobular structures of early parous women from those of nulliparous women
has been demonstrated through the enriched analysis of the genomic profile of breasts of
parous and nulliparous postmenopausal and premenopausal women 9, 10 and of rodent
models 11, 12. These findings have allowed researchers to demonstrate that significant
differences in the expression of genes controlling differentiation and transcription exist
between groups that differ in their parity history. These data explain at molecular level the
basis of the protective effect of pregnancy and establishes a functional genomic signature of
breast cancer risk reduction, confirming a postulate published in 1997 7.
In the present work we present novel findings that emanated from a detailed histological,
cytological, immunohistochemical and transcriptomic analysis of breast samples obtained
from nulliparous and parous postmenopausal women. Our data demonstrate that the
differentiation of the breast induced by an early pregnancy imprints a specific phenotypic
and genotypic signature that can be detected in post-menopausal women.
Material and Methods
Data and sample collection
For determining whether the phenotype and the pattern of gene expression differed between
nulliparous and parous postmenopausal women, breast tissue was collected from
volunteering healthy women residing in Norrbotten County, Sweden, a homogeneously
ethnic population of Swedish and Finnish ancestry. Study subjects were recruited between
September 2008 and May 2009 at the Mammography Department of Sunderby Hospital,
Luleå, Sweden (Study Protocol number 08-020M). The eligibility criteria included women
between 50 and 69 years of age, postmenopausal; i.e., lack of menstrual periods for 12
preceding months and elevated circulating levels of follicle stimulating hormone (FSH) (40–
250 IU/L), consistent with menopausal condition.
All volunteers signed an informed consent to participate in the study and to donate breast
tissues as core needle biopsies (CNB) and blood. Breast core biopsies were taken from the
upper outer quadrant of the right or the left breast under radiographic control. From the
CNBs obtained from each donor one core was fixed in 70% ethanol for histological and
immunohistochemical (IHC) analysis; the two remaining cores were placed in RNAlater®
(Ambion) solution for RNA extraction and subsequent transcriptomic analysis. All samples
obtained were stripped of any personal identifiers and assigned random numbers that were
linked to each subject’s identifiable information which was accessible only to authorized
personnel in Sweden 13. All laboratory personnel were blinded to samples’ parity status and
other personal information. Unblinding of the parity status after completion of cDNA
microarray analysis revealed that volunteer participants belonged to one of the following
groups: Parous (P), 71 women that were 23.2 (±4.25) years old at the time of their first
pregnancy and 24.0 (±4.6) at the time of delivery of a first full term pregnancy (FTP); this
group included women that had been pregnant once or more times (gravida ≥1), and
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delivered one or more live children (parity ≥1) (G≥1/P≥1); nulligravida nulliparous (NN), 30
women who never became pregnant and therefore never delivered a live child (G0/P0), and
gravida-nulliparous (GN), 12 women that became pregnant one or more times, but never
delivered a live child (G≥1/P0). Pregnancies in 11 of the women in this group were
terminated between the 6th to 12th week of gestation, and one had a miscarriage at the 20th
week of pregnancy. Because of the similarities in gene expression levels between NN and
GN these two groups were further analyzed as a single group of nulliparous (NP) women.
Methods
Morphological analysis of the architecture of the breast
All ethanol-fixed cores were processed for histopathological and IHC evaluation. All blocks
of paraffin-embedded tissues were cut at a thickness of 5 μm, stained with hematoxylin and
eosin (HE) and examined under an Olympus BH-2 transmitted light microscope. Each
section was evaluated for the presence of mammary ducts and lobules and for determining
the ratio between parenchyma and stroma. Specimens lacking epithelial components were
not included in the analysis.
Immunohistochemical (IHC) analysis
Fifty cases (21 NP and 29 P) were selected for IHC detection of the following antibodies:
cytokeratin (CK) 5/6, clone D5/16 B4, ER-α clone ID5, dilution 1:50; progesterone receptor
(PR) (clone PgR 636); smooth muscle antibody (SMA) clone 1A4, and Ki67, all from
DakoCytomation; anti-di-methyl-histone H3 (Lys9) (H3K9me2) and tri-methyl histone H3
(Lys27) (H3K27me3) (Cell Signaling Technology Inc.), and cyclin L2 (CCNL2) antibody
(Novus Biologicals, Cambridge, UK). All assays were run with appropriate negative and
positive controls; incubation and staining procedures were performed following protocols
recommended by the manufacturers. Evaluation of IHC reactions was performed by a count
of 1,000 cells per case and results were expressed as the percentage of positive nuclei (ER-
α, PR, Ki67, H3K9me2, H3K27me3 and CCNL2) or cytoplasm (CK 5/6, SMA) of the total
number counted and analyzed by t-test. Cells were evaluated according the intensity of
brown staining as strongly positive (+); moderately positive (±), or negative (−).
Image analysis
In normal cells, changes in the chromatin appearance reflect changes in the activation
patterns of genes. Features describing the chromatin distribution pattern are referred to as
nuclear texture features that are sensitive to the differences between the various descriptive
classes of chromatin patterns. In this work we analyzed in hematoxylin-stained slides of
breast tissues from four nulliparous and five parous women the nuclear texture features of
interphase nuclei of epithelial cells using the Carl Zeiss/Kontron equipment and
methodology previously described 14, 15. The threshold low (L) and high (H) levels were
defined such that the nuclear images appeared pseudocolorized green and well separated
from each other and from the background (in the present case L = ~86 and H = ~200 gray
values). Quantitative information on the following geometric, densitometric and textural
parameters was obtained: nuclear area (μm2), nuclear perimeter (μm), nuclear feret ratio (=
minimum feret/maximal feret), mean gray value per nucleus, standard deviation of the total
densitometric values per nucleus or absorbance variability per nucleus (SDtd), entropy and
energy 14–17.
Gene analysis
For microarray gene analysis total RNA was isolated from the core biopsy samples using the
Qiagen Allprep RNA/DNA Mini Kit (Qiagen, Alameda, CA, USA) according to
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manufacturer’s instructions. The GeneChip Expression 3′-Amplification Two-Cycle cDNA
Synthesis Kit (Affymetrix, Santa Clara, CA) was used for the Affymetrix microarray gene
analysis. A total of 169 chips were run; from these, 113 chips, 71 from P and 42 from NP,
were selected for the differential expression analysis of parous vs. nulliparous after
completion of standard Affymetrix quality control measures (average background, scale
factors, percent present calls) and probe-level model (PLM) analysis. Nineteen good quality
chips that represented technical replicates were excluded from the P/NP comparison.
Biostatistical analysis
Affymetrix CEL files were pre-processed using RMA 18, which incorporates background
adjustment, quantile normalization of probe intensities across arrays, and summarization
using the median polish algorithm. To account for between-batch variability in the arrays,
the data were adjusted using ComBat, an empirical Bayes framework developed by Johnson
et al. 19. A variance filter was applied for removing all probesets with variance across all
samples below the first quartile. A total of 18,694 probesets remained for further analysis
after filtering. The limma package 20, which uses empirical Bayes methods to moderate
standard errors of model coefficients (i.e., log [base 2] fold-changes), was implemented in
the R/Bioconductor platform 21 that was used for identifying probesets differentially
expressed in the P/NP comparisons. Probesets for downstream analysis from pairwise
comparisons were selected using both the p-value of 0.001 from the empirical Bayes
moderated t-statistics, and a minimum log2 fold-change of 0.3 threshold as criteria of
significance; unless otherwise noted. A heatmap using the RMA expression values and
average linkage method to make hierarchical clustering on selected genes was built for
depicting the genes that were differentially expressed between parous and nulliparous
women. Data mining methods were applied for identifying statistically significant biological
processes, pathways and gene networks that were differentially expressed in the P/NP
comparisons. Gene ontology (GO) functional categories enriched in differentially expressed
genes were identified using conditional hyper-geometric tests in the GOstats package (R/
BioConductor). This analysis was carried out independently for up and down regulated
genes; a p-value cut off of 0.01 was used to select GO terms.
To identify pathways and associations to other knowledge datasets, Gene Set Enrichment
Analysis (GSEA) was performed against the lists of differentially expressed genes. Since we
were interested in finding pathways and co-regulated genes, we relaxed the p-value to 0.01
and did not apply any fold change filter to identify pathways from more genes. Pathways
obtained from MSigDB (database of gene sets provided by GSEA) were tested for
enrichment. Default parameters were chosen, except that the maximum intensity of probes
was only selected while collapsing probe sets for a single gene. The gene expression profile
obtained was deposited to the Gene Expression Omnibus (GEO) Series GSE26457: (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=zpmfjygscwaemdo&acc=GSE26457).
Gene validation through Real-Time RT-PCR
RNA was reverse-transcribed (RT) using the M-MLV reverse transcriptase (Ambion) and
anchored oligo-dT. For each sample, two RT reactions were performed with 50 ng or 12.5
ng of total RNA in 50 μl final. Minus RT controls were included. For one sample arbitrarily
chosen as calibrator, a 4-fold 5-points standard curve was performed. Aliquots (5 μl) of
cDNA were used for PCR. Real-time Taqman PCR Assays-on-Demand from Applied
Biosystems were run using Universal PCR master mix from Applied Biosystems on a 7900
HT instrument. Cycling conditions were 95°C, 15 min followed by 40 (2-step) cycles (95°C,
15 sec; 60°C, 60 sec). The levels of transcripts were expressed as relative quantities to the
level in the calibrator. For each sample, the values were averaged and standard deviation of
data from two PCR reactions performed with the cDNAs from the two RT reactions. Two-
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tailed unpaired t-tests were used for analysis of significance; p<0.01 was considered
statistically significant.
Results
Architecture of post-menopausal women’s breast
The breast tissues of the parous and nulliparous women contained ducts and lobules type 1
(Lob 1), which were characterized by containing 11.2 ± 6·3 ductules per lobular unit, as
previously reported 7–9. Each ductule was composed of an external layer of myoepithelial
cells and a monolayer of cuboidal epithelial cells lining a lumen than contained
proteinaceous material (Fig. 1a–d). IHC staining revealed that epithelium lining both ducts
and ductules consisted of basal cells showing positive reactivity for keratin 5/6 (Fig. 1e) and
myoepithelial cells reacting positively with SMA (Fig. 1f); these two markers had similar
reactivity in both parous and nulliparous breasts.
The proliferative activity of the epithelial cells or Ki67 index, was expressed as the
percentage of Ki67 positive cells from the total number of cells counted in ducts and Lob 1
of parous (Fig. 2A-a,b) and nulliparous (Fig. 2A-c,d) women’s breast. The Ki67 index in the
ductal epithelium of NP breasts’ was significantly higher (P<0.03) than in the Lob 1 of the
same tissues and it was also higher than in ducts and Lob 1 of the parous breast (Fig. 2B). In
the parous breast, on the other hand, the Ki67 index did not differ between the epithelium of
ducts and that of Lob 1 (p>0.55) (Fig. 2B).
The ER-α and the PR (data not shown) were equally expressed in epithelial cells lining
ducts and Lob 1 of both NP and P breast tissues. The percentage of cells positive for both
receptors did not differ between NP and P women’s breasts, as shown in the box plot of ER-
α positive cells (Supplemental Figure 1S).
Chromatin pattern in epithelial cells of the nulliparous and parous breast
The study of HE-stained tissues revealed that the population of luminal cells lining ducts
and Lob 1 was composed of cells that were characterized by their nuclear appearance into
two types: one that contained large and palely stained nuclei with prominent nucleoli (Fig.
1-a,b) and another consisting of small hyper chromatic nuclei (Fig. 1-c,d). The pale staining
of the large former nuclei is a feature indicative of a high content of non-condensed
euchromatin; these nuclei were called euchromatin-rich nuclei (EUN) (Fig. 1-a,b). The
hyperchromasia observed in the latter nuclei was indicative of chromatin condensation and
high content of heterochromatin; these nuclei were identified as heterochromatin-rich
nucleus (HTN) (Fig. 1-c,d and Fig. 3A). The analysis of the distribution of HTN and EUN
cells in histological sections of the breast core biopsies revealed that EUN were more
abundant in the NP than in the P breast tissues, whereas the inverse was true for the HTN;
these differences were statistically significant (Fig. 3B). We have confirmed the differences
between the HTN and EUN depicted in figures 1-a,b vs. 1-c,d, using a quantitative image
analysis system. The nuclear size (diameter, area and perimeter) of the EUN as a whole was
significantly higher (P<0.05) than that of the HTN in both nulliparous and parous women
(Table 1 and Fig. 3B). Differences were also found to be statistically significant (p<0.05)
regarding the nuclear shape (nuclear feret ratio) in the breast of nulliparous women,
indicating that in these breasts the nuclei of the HTN had a more elongated ellipsoidal shape
than the EUN (Table 1). The light absorbance (mean gray values/nucleus) was always
greater for EUN than for HTN of both NP and P breasts, either considered as two groups or
individually, an indication that under densitometric terms HTN were always more densely
stained than EUN. Comparison of the EUN of nulliparous vs. parous breasts revealed
significant differences in nuclear size, stainability and densitometric energy, leading us to
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conclude that epithelial cell nuclei were larger, less stainable and with smaller regions with
uniform densitometric intensity in nulliparous breasts. Comparison of the HTN of
nulliparous vs. parous breasts revealed significant differences in nuclear diameter (Fig. 3A),
perimeter, shape and stainability; cell nuclei showed larger contours and more elongated
ellipsoidal shape and they were more stainable in nulliparous breasts (Table 1). These
observations indicated that a shift of the EUN cell population to a more densely packed
chromatin cell (HTN) had occurred in association with the history of pregnancy as a
distinctive pattern of the postmenopausal parous breast.
Since chromatin condensation is part of the process of chromatin remodeling towards gene
silencing that is highly regulated by methylation of histones, we verified this phenomenon
by IHC incubating NP and P breast tissues with antibodies against histone 3 dimethylated at
lysine 9 (H3K9me2) (Figs. 4A and 4B) and trimethylated at lysine 27 (H3K27me3) (Figs. 4C
and 4D). The IHC stain revealed that methylation of H3 at both lysine 9 and 27 was
increased in the heterochromatin condensed nuclei of epithelial cells of the parous breast
(Figs. 4A-b and 4C-b) when compared to the euchromatin rich nuclei of the nulliparous
breast (Figs. 4A-a and 4C-a). In the nulliparous breast the reactivity in individual cells was
less intense and the number of positive cells was significantly lower (Fig. 4B and 4D). These
variations in chromatin reorganization were supported by the upregulation of CBX3, CHD2,
L3MBTL, and EZH2 genes controlling this process, as depicted in Table 2.A and Figure 5.
Transcriptomic differences
Analysis of P and NP microarrays revealed that there were 305 differentially expressed
probesets, 267 up- and 38 down-regulated, corresponding to 208 distinct genes between
these two groups. From these 267 genes we selected those that described biological
processes that were representative of the transcriptomic differences between the parous and
the nulliparous breasts. Using bioinformatics based analysis of microarray data we found
that the biological processes involving the splicing machinery and mRNA processing were
prevalent in the parous breast and were represented by the following upregulated genes:
LUC7L3, SFRS1, HNRNPA2B1, HNRNPD, RBM25, SFRS5, METTL3, HNRNPDL, and
SFPQ (Table 2A). Transcription regulation and chromatin organization were also highly
represented in the parous breast by the upregulation of CBX3, EBF1, GATA3, RBBP8,
CCNL1, CCNL2, CDCA7, EZH2, FUBP1, NFKBIZ, RUNX3, ZNF107, ZNF207, ZNF692,
ZNF711, ZNF789, CDCA7, and ZNF692 (Table 2A). The parous breast also expressed
upregulation of six non coding regions that included XIST, MALAT-1 (or NEAT2) and
NEAT1 (Table 2C).
Genes that were downregulated in the parous breast represented transcription regulation,
encompassing CBL, FHL5, NFATC3, NCR3C1, TCF7L2, and a set of genes that were
involved in IGF-like growth factor signaling, somatic stem cell maintenance, muscle cell
differentiation and apoptosis, such as IGF1, RASD1, EBF1, SOX 1, SOX6, SOX 17,
RALGAPA2 and ABHD5 (Table 2B). The level of expression was confirmed to be
differentially expressed between nulliparous and parous breast tissues by real time RT-PCR
for the following genes: CREBZF, XIST, MALAT1, NEAT1, CCNL2, GATA3, DDX17,
HNRPDL, SOX6, SNHG12, SOX 17 and C1orf168. In addition to the level of expression,
the localization of the alternative splicing regulator cyclin-cyclin L2 protein (CCNL2) 22
was verified by IHC. CCNL2 protein was expressed in the nucleus of epithelial cells in
breast tissues from NP and P women, although the level of expression was significantly
higher in Lob 1 in the parous breast when compared with similar structures found in the
breast of nulliparous women (Results not shown). These observations confirmed the
localization of this gene product in the splicing factor compartment (nuclear speckles) 23.
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Discussion
Our previous studies have in great part clarified the role of pregnancy-induced breast
differentiation in the reduction in breast cancer risk, as well as the identification of Lob 1 or
the terminal ductal lobular unit (TDLU) as the site of origin of breast cancer 6–9, 24. The
morphological, physiological and genomic changes resulting from pregnancy and
hormonally-induced differentiation of the breast and their influence on breast cancer risk
have been addressed in previous publications 6–9, 24, 25. Our observations that during the
post-menopausal years the breast of both parous and nulliparous women contains
preponderantly Lob 1 and the fact that nulliparous women are at higher risk of developing
breast cancer than parous women indicate that Lob 1 in these two groups of women either
differ biologically, or exhibit different susceptibility to carcinogenesis 25. For clarifying this
concept the present manuscript places major emphasis on the changes in cell types and
increases in chromatin condensation as novel markers for defining the concept of
differentiation in the adult breast. These findings confirm the universality of the histone 3
methylation in lysines 9 and 27 during differentiation, since a similar phenomenon has been
described to occur during embryonic stem cell (ESC) differentiation 26. The observed
chromatin changes in parous epithelial cells are complemented by the expression of genes
related to increasing cell adhesion and differentiation, such as NRXN1, DSC3, COL27A1,
PNN, COL4A6, LAMC2, COL7A1, COL16A1, and LAMA3, and MGP, KRT5, GATA3
and LAMA3, respectively.,
In contrast to the findings of Asztalos et al.10 of downregulation of the expression of ER-α
following recent (<2 years) and distant (5 to 10 years) pregnancies in premenopausal
women, our current genomic and IHC study did not reveal differences in the level of
expression of ER-α in the epithelial cells of ducts and Lob 1 between parous and nulliparous
postmenopausal women. Nevertheless, numerous genes that are regulated downstream by
the ER-α were found to be upregulated in the parous breast, supporting a-parity mediated
protective effect evident in younger parous women 10 but lasting until menopause. Among
the ER-α downstream regulated genes was GATA3, which encodes a protein that belongs to
the GATA family of transcription factors that regulates T lymphocyte differentiation and
maturation. GATA3 is crucial to mammary gland morphogenesis and differentiation of
progenitor cells and a putative tumor suppressor 27. Induction of GATA 3 expression in
GATA3-negative undifferentiated carcinoma cells is sufficient to induce tumor
differentiation and inhibition of tumor dissemination 28. Therefore, the observation that
genes involved in the estrogen receptor regulated pathways are upregulated in the parous
breast in spite of the lack of transcriptomic differences in this receptor’s levels between
parous and nulliparous postmenopausal breast tissues suggests that they could be under
permanent transcriptional modification as a manifestation of a higher degree of cell
differentiation.
Studies of breast development under the influence of parity in women and in animal models
are in agreement on the pregnancy-induced differentiation of the breast, a process that
ultimately becomes manifested as a specific genomic signature in the mammary gland 6–12.
Although variations in gene expression among different studies and species are expected, an
increase in immune activity, including overexpression of lipopolysaccharide binding protein
(LBP/Lbp) has been reported in the post-pregnancy breast of premenopausal women 10 and
in the mammary gland of four different strains of rats 12. Interestingly, this response
observed in both recently pregnant in distant pregnant groups was not observed in the
postmenopausal group reported in this study. These discrepancies might indicate that the
upregulation of inflammation/immune response–related genes persists during post-partum
involution, but wanes after menopause sets in. However, it cannot be ruled out the
possibility that the cyclic hormonal changes occurring during the menstrual/estrus cycle
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influence the genomic profile of the breast activating pathways that greatly differ from those
expressed in the postmenopausal parous women.
Importantly, we found a shift in the cell population of the postmenopausal breast as a
manifestation of the reprogramming of the organ after pregnancy. These observations are in
agreement with what is observed in the rat mammary gland, which also contains two types
of luminal epithelial cells, designated dark (DC) and intermediate (IC) cells, in addition to
the myoepithelial cells.29 The DC and IC are equivalent to the HTN and EUN cells
described in the present work. DCs increase after pregnancy and lactational involution;
whereas the ICs significantly outnumber the DC in ductal hyperplasias and ductal
carcinomas 29, 30. Our analysis of nuclear ultrastructural and morphometric parameters of
rodent IC have allowed us to differentiate the mammary progenitor stem cell from the
cancer stem cells 25, 29, 30. Nuclear morphometric analysis of breast and ovarian carcinomas
has confirmed the predictive value of nuclear grade on the progression of premalignant
lesions to invasiveness 31–33. Our present findings of a significant decrease in the number of
EUN with a subsequent increase in the number of HTN cells expressing specific biomarkers
identified at the chromatin and transcriptional levels support the value of morphometric
analysis as an adjuvant to molecular studies[Figure 4. A–D]. Our data clearly indicate that
there are morphological indications of chromatin remodeling in the parous breast, such as
the increase in the number of epithelial cells with condensed chromatin and increased
reactivity with anti-H3K9me2 and H3K27me3 antibodies. Histone methylation is a major
determinant for the formation of active and inactive regions of the genome and is crucial for
the proper programming of the genome during development 34. In the parous breast there is
upregulation of transcription factors and chromatin remodeling genes such as CHD2 or
chromodomain helicase DNA binding protein 2 and the CBX3 or Chromobox homolog 3,
whose products are required for controlling recruitment of protein/protein or DNA/protein
interactions. CBX3 is involved in transcriptional silencing in heterochromatin-like
complexes, and recognizes and binds H3 tails methylated at lysine 9, leading to epigenetic
repression. Two other important genes related to the polycomb group (PcG) protein that are
upregulated in the parous breast are the L3MBTL gene or l(3)mbt-like and the histone-lysine
N-methyltransferase or EZH2. Members of the PcG form multimeric protein complexes that
maintain the transcriptional repressive state of genes over successive cell generations. EZH2
is an enzyme that acts mainly as a gene silencer, performing this role by the addition of three
methyl groups to lysine 27 of histone 3, a modification that leads to chromatin
condensation 26, 35, 36.
Recent studies indicate that RNA molecules recruit PcG complexes to the locus of
transcription or to sites located elsewhere in the genome. An important role has been
attributed to noncoding RNAs (ncRNAs) 37. It is possible to postulate that the increased
chromatin condensation in the parous breast reported herewith could have been initiated by
ncRNAs, a postulate supported by the observed upregulation of several ncRNAs that
included nuclear paraspeckle assembly transcript 1 (NEAT1), MALAT-1 (NEAT2), and X
inactive specific transcript (XIST) 38, all critical components of the speckles. The expression
of MALAT-1 is upregulated by the neurotransmitter oxytocin during lactation, which acts
through its specific receptor OTR. It is of interest the fact that both OTR and MALAT-1
remain upregulated in the breast of postmenopausal parous women even in the absence of
circulating oxytocin. These observations indicate that in parous women the breast remains
actively involved in the RNA metabolism that is necessary for maintaining a state of
differentiation. Up-regulation of XIST occurs upon differentiation, resulting in X
chromosome inactivation. A ncRNA transcribed from a portion of the Xist gene locus forms
hairpin structures that recruit the PRC2 complex to the X-inactivation center X(ic) 39.
Transcription of full-length Xist RNA, which forms the same hairpin structures, leads to
further PRC2 recruitment and the spread of PcG-mediated repression across the inactive X
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chromosome. Xist repression, which is often seen in malignancies, also occurs in early
embryogenesis and during the acquisition of pluripotency in undifferentiated ES cells by the
binding of Nanog, Oct4 and Sox2 directly to the chromatin of the Xist gene 39. It is possible
that in the postmenopausal nulliparous breast the upregulation of DDX, Sox 1, Sox 6 and
Sox 17, which might be equivalent to Nanog, Oct4 and Sox2, play a direct pivotal role in the
repression of XIST transcription. Although this postulate needs to be functionally verified, it
is possible that these genes may play a role in controlling XIST in the parous breast. The
upregulation of XIST has important implications in the understanding of the differentiation
pattern of the parous breast. In recent studies it has been shown that the reprogramming of
X-chromosome inactivation during the acquisition of pluripotency in vivo and in vitro is
accompanied by the repression of XIST 39–41. Reprogramming experiments have further
reinforced the concept that X-inactivation is intimately linked to differentiation and support
our findings that XIST is expressed in adult well differentiated cells, participating in the
maintenance of gene repression 39–41. There is a relationship between the chromatin
remodeling process and post transcriptional control maintained by the spliceosome
machinery that is stored in nuclear speckles. Among the components of the spliceosome
machinery that are up-regulated in the parous breast are the heterogeneous nuclear
ribonucleoproteins HNRPA3, HNRPA2B1, HNRPD and the HNRPU shown in Table 2A.
The functional role of these HNRPs in the postmenopausal breast could be implicated in the
regulation of mRNA stability, other functions like mammary gland involution 42, acting as
negative regulators of telomere length maintenance 43 or regulating the trafficking of mRNA
molecules 44. Other members of the spliceosome complex are the small nuclear
ribonucleoproteins (snRNPs), which function as suppressors of tumor cell growth and may
have major implications as cancer therapeutic targets. Among these we have found that the
transcripts regulated by the genes SF3B1, SFRS2, SFRS7, SFRS8, SFRS14, SFRS16,
SNRP70,, SNRPB, SNRPA1, PRF3 and PHF5A are overexpressed in the parous breast.
Other members of the splicing factor compartment that are localized in the nuclear speckles
are CCNL1 and CCNL2. We have demonstrated through immunohistochemistry that
CCNL2 protein is overexpressed in the nucleus of epithelial cells composing the Lob 1 of
the parous breast. CCNL1 and CCNL2 are transcriptional regulators that participate in the
pre-mRNA splicing process and the expression of critical factors leading to cell apoptosis,
possibly through the Wnt signal transduction pathway 45, 46, which we found to be down-
regulated in the parous breast.
Another component of the spliceosome complex that regulates genes involved in the
apoptotic process is the RNA binding motif protein 5 (RBM5). The overexpression of
RBM5 retards ascites associated tumor growth and enhances p53-mediated inhibition of cell
growth and colony formation 47, 48, mechanisms that could also be operational in the parous
breast. The spliceosome plays a critical role in differentiating mouse ESC, and self-renewal,
pluripotency and tissue lineage specification of human ESC 49. Post-transcriptional
modifications of RNA, including packaging into the nuclear speckles of the breast epithelial
cells and recognition by RNA-binding proteins and/or microRNAs are crucial processes in
differentiating breast epithelial cells. Although it is known that these regulatory mechanisms
decrease the susceptibility of the cell to carcinogenesis, more studies need to be conducted
for identifying the specific pathways involved in this process. Data presented here contribute
to emphasize the importance of post-transcriptional regulatory mechanisms as a critical
component underlying the differentiation of the breast.
In summary, in the present work we clearly demonstrate that the breast of parous
postmenopausal women exhibits a specific signature that has been induced by a full term
pregnancy. This signature reveals for the first time that the differentiation process is
centered in chromatin remodeling and the mRNA processing reactome, which emerge as
important regulatory pathways induced by pregnancy. This study is strengthened by the
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homogeneity of a population restricted to participants of Swedish or Finnish ethnicity
residents of the northernmost part of Sweden because it avoids variations in gene expression
resulting from differences in ethnicity rather than parity. Nevertheless, it also represents a
limitation and emphasizes the need of confirming these results in ethnically different and
varied populations. The biological importance of the pathways identified in this specific
population cannot be sufficiently emphasized due to the fact that the upregulation of the
non-coding sequences that control gene repression and of the genes that control the
spliceosomes could represent a safeguard mechanism at genomic and at post-transcriptional
level that maintains the fidelity of the transcription process, a phenomenon that could be the
ultimate step mediating the protection of the breast conferred by full term pregnancy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty
This article demonstrates that an early pregnancy induces lifetime changes in the breast
epithelium which are detected in postmenopausal women as a genomic signature that is
characterized by chromatin remodeling and post-transcriptional modifications of RNA.
These findings explain at molecular level the mechanisms mediating the protective effect
conferred by an early pregnancy.
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Impact
The identification of a specific genomic signature of pregnancy has uncovered a novel
tool that will serve as a surrogate biomarker for testing new chemopreventive agents and
will significantly advance the field of cancer prevention.
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Figure 1.
Histological sections of HE-stained ductules in lobules type 1 (Lob 1): a and b, from
nulliparous (NP), and c and d from parous (P) women’s breast tissues; e, positive IHC stain
for keratin 5/6 in basal cells; f, IHC stain for SMA in myoepithelial cells. DAB with
hematoxylin (H) counterstain. Magnification bar: 100 μm.
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Figure 2.
A. Ki 67 immunoreactivity in the nucleus of epithelial cells in ducts (a) and Lob 1 (b) in the
parous breast and in ducts (c) and Lob 1 (d) of the nulliparous breast. DAB-H counterstain;
magnification bar: 100 μm. B. Box plot of the proliferative activity (Ki67 index) of ductal
and Lob 1 epithelial cells. The Ki67 index in ductal epithelial cells of the nulliparous breast
(NP-ducts) was significatively higher than in the Lob 1 (NP-Lob) of the same tissues (Paired
t-test) (T=2.22; p<0.03), but it did not differ significatively between ducts (P-ducts) and Lob
1 (P-Lob) in the parous breast. The Ki 67 index in NP-ducts was also significative higher
than in ducts and Lob 1 of the parous breast.
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Figure 3.
A. The H3K9(me2) IHC staining is of higher (+) intensity in the nuclei of the P (b) breast
than in NP breast (a); a moderately diffuse (±) stain predominates in most of the NP breast.
DAB-H counterstain. Magnification bar: 100 μm. B. Box plot shows a significantly higher
number of strongly positive cells (+) in P than in NP breasts (p<0.001); moderately positive
(±) cells predominate in the NP tissues (p<0.00001), and negative cells are more numerous
in the P cells (p<0.05). C. IHC reaction of H3K27(me3) is of higher (+) intensity in the
nuclei of the P (b) breast than in NP breast (a), in which the nuclear stain is faint and finely
granular, being mostly circumscribed to the nucleoli. DAB-H counterstain. Magnification
bar: 100 μm. D. Box plot shows a significantly higher number of strongly positive cells (+)
in P than in NP breasts (p<0.0005); weakly to moderately positive (±) cells predominate in
the NP tissues (p<0.00005); negative cells are more numerous in the P than in the NP breast
cells (p<0.06).
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Figure 4.
A. Transcriptionally active chromatin is predominantly expressed in the euchromatin-rich
nuclei (EUN) of the nulliparous women’s breast. B. Transcriptionally inactive chromatin is
more frequently found in the heterochromatin-rich nuclei (HTN) of the parous breast; its
presence is associated with histone 3 methylation at lysines 9 and 27, and transcriptional
silencing in heterochromatin complexes.
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Table 1
Image analysis geometric, densitometric and textural parameters for hematoxylin-stained interphase nuclei
from epithelial cells of postmenopausal nulliparous (NP) and parous (P) women. EUN, euchromatin-rich
nucleus; HTN; heterochromatin-rich nucleus; x̄ ± SD, Mean ± standard deviation; ANOVA; NS, no
significant..
Nuclear Characteristics
Reproductive History
Nulliparous (NP) Parous (P)
Chromatin Pattern
EUN
x̄ ± SD
HTN
x̄ ± SD
EUN
x̄ ± SD
HTN
x̄ ± SD
Area (μm2) 27.40±7.471 16.37±5.082 24.38±6.933 15.99±4.794
Perimeter (μm) 24.20±5.341,5 18.42±3.722,3 22.30±4.793,7 16.97±3.014,8
Feret Ratio 0.72±0.111,9 0.62±0.142,10 0.72±0.113,11 0.71±0.124,12
Mean Gray value/nucleus 198.64±11.141,13 167.96±14.582,14 193.85±15.903,15 182.90±15.354,16
Entropy 5.69±0.261,17 5.85±0.322,18 5.66±0.413,19 5.81±0.344,20
Energy 0.022±0.0051,21 0.019±0.0042,22 0.024±0.0123,23 0.021±0.0064,24
1EUN vs. 2HTN (p<0.05); 3EUN vs. 4HTN (p<0.05); EUN 1 vs. 3 (P>0.000); HTN 2 vs. 4 (NS); EUN 5 vs. 7 (P>0.000); HTN 6 vs. 8 (p<0.004);
EUN 9 vs. 11 (NS); HTN 10 vs. 12 (p<0.000); EUN 13 vs. 15 (0.000); HTN 14 vs. 16 (p<0.000); EUN 17 vs. 19 (NS); HTN 18 vs. 20 (NS);
EUN 21 vs. 23 (p<0.001); HTN 22 vs. 24 (NS).
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Table 2
Genes displaying differential expression between parous and nulliparous breast tissues classified according to
biological processes
Symbol Log Ratio P value Gene Name
Apoptosis (GO:0006915;GO:0006917;GO:0008624;GO:0042981)
CASP4 0.37 0.0003 caspase 4, apoptosis-related cysteine peptidase
RUNX3 0.36 0.0000 runt-related transcription factor 3
LUC7L3 0.34 0.0002 LUC7-like 3 (S. cerevisiae)
ELMO3 0.30 0.0003 engulfment and cell motility 3
DNA repair (GO:0006281; GO:0006284)
SFPQ 0.46 0.0002 splicing factor proline/glutamine-rich
MBD4 0.36 0.0003 methyl-CpG binding domain protein 4
RBBP8 0.32 0.0000 retinoblastoma binding protein 8
Cell adhesion (GO:0007155; GO:0030155)
NRXN1 0.60 0.0001 neurexin 1
DSC3 0.51 0.0000 desmocollin 3
COL27A1 0.44 0.0002 collagen, type XXVII, alpha 1
PNN 0.37 0.0001 pinin, desmosome associated protein
COL4A6 0.36 0.0008 collagen, type IV, alpha 6
LAMC2 0.34 0.0008 laminin, gamma 2
COL7A1 0.33 0.0002 collagen, type VII, alpha 1
COL16A1 0.31 0.0000 collagen, type XVI, alpha 1
LAMA3 0.30 0.0008 laminin, alpha 3
Cell cycle (GO:0000075; GO:0007049; GO:0045786)
SYCP2 0.45 0.0000 synaptonemal complex protein 2
PNN 0.37 0.0001 pinin, desmosome associated protein
RUNX3 0.36 0.0000 runt-related transcription factor 3
RBBP8 0.32 0.0000 retinoblastoma binding protein 8
Cell differentiation (GO:0001709; GO:0030154; GO:0030216)
MGP 0.53 0.0003 matrix Gla protein
KRT5 0.41 0.0002 keratin 5
GATA3 0.35 0.0009 GATA binding protein 3
LAMA3 0.30 0.0008 laminin, alpha 3
Cell proliferation (GO:0008283; GO:0008284; GO:0008285; GO:0042127; GO:0050679; GO:0050680)
PTN 0.67 0.0002 Pleiotrophin
KRT5 0.41 0.0002 keratin 5
RUNX3 0.36 0.0000 runt-related transcription factor 3
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Symbol Log Ratio P value Gene Name
IL28RA 0.34 0.0003 interleukin 28 receptor, alpha (interferon, lambda receptor)
CDCA7 0.31 0.0005 cell division cycle associated 7
Cell motility (GO:0006928; GO:0030334)
DNALI1 0.37 0.0001 dynein, axonemal, light intermediate chain 1
LAMA3 0.30 0.0008 laminin, alpha 3
G-protein coupled receptor pathway (GO:0007186)
OXTR 0.54 0.0006 oxytocin receptor
RNA metabolic process (GO:0000398; GO:0001510; GO:0006376; GO:0006396; GO:0006397; GO:0006401; GO:0008380)
METTL3 0.69 0.0000 methyltransferase like 3
HNRPDL 0.65 0.0001 heterogeneous nuclear ribonucleoprotein D-like
HNRNPD 0.59 0.0003 heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa)
HNRNPA2B1 0.56 0.0003 heterogeneous nuclear ribonucleoprotein A2/B1
SFPQ 0.47 0.0006 splicing factor proline/glutamine-rich
RBM25 0.38 0.0009 RNA binding motif protein 25
RBMX 0.38 0.0000 RNA binding motif protein, X-linked
LUC7L3 0.34 0.0002 LUC7-like 3 (S. cerevisiae)
SFRS1 0.30 0.0001 splicing factor, arginine/serine-rich 1
RNA transport (GO:0050658)
HNRNPA2B1 0.56 0.0003 heterogeneous nuclear ribonucleoprotein A2/B1
Transcription (GO:0006350; GO:0006355; GO:0006357; GO:0006366; GO:0016481; GO:0045449; GO:0045893; GO:0045941)
HNRPDL 0.65 0.0001 heterogeneous nuclear ribonucleoprotein D-like
HNRNPD 0.59 0.0003 heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa)
CBX3 0.53 0.0003 chromobox homolog 3 (HP1 gamma homolog, Drosophila)
NFKBIZ 0.48 0.0001 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
FUBP1 0.47 0.0002 far upstream element (FUSE) binding protein 1
SFPQ 0.47 0.0006 splicing factor proline/glutamine-rich
EZH2 0.44 0.0000 enhancer of zeste homolog 2 (Drosophila)
ZNF207 0.41 0.0007 zinc finger protein 207
ZNF711 0.41 0.0003 zinc finger protein 711
GATA3 0.38 0.0009 GATA binding protein 3
PNN 0.37 0.0003 pinin, desmosome associated protein
ZNF107 0.37 0.0001 zinc finger protein 107
RUNX3 0.36 0.0000 runt-related transcription factor 3
CCNL1 0.35 0.0009 cyclin L1
ZNF692 0.34 0.0000 zinc finger protein 692
CHD2 0.33 0.0001 chromodomain helicase DNA binding protein 2
RBBP8 0.32 0.0000 retinoblastoma binding protein 8
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Symbol Log Ratio P value Gene Name
ZNF789 0.32 0.0005 zinc finger protein 789
CDCA7 0.31 0.0005 cell division cycle associated 7
Chromatin organization (GO:0006333; GO:0006338)
CBX3 0.53 0.0003 chromobox homolog 3 (HP1 gamma homolog, Drosophila)
CHD2 0.33 0.0001 chromodomain helicase DNA binding protein 2
Cell division (GO:0051301)
SYCP2 0.45 0.0000 synaptonemal complex protein 2
DNA metabolic process (GO:0006139; GO:0006260; GO:0006310; GO:0015074)
METTL3 0.69 0.0000 methyltransferase like 3
SFPQ 0.46 0.0002 splicing factor proline/glutamine-rich
GOLGA2B 0.32 0.0001 golgin A2 family, member B
Lactation (GO:0007595)
OXTR 0.54 0.0006 oxytocin receptor
Apoptosis (GO:0006917)
SOS1 −0.23 0.0040 son of sevenless homolog 1
Cell adhesion (GO:0007155; GO:0030155)
PDZD2 −0.35 0.0004 PDZ domain containing 2
Cell proliferation (GO:0008283; GO:0008284; GO:0008285; GO:0042127; GO:0050679; GO:0050680)
IGF1 −0.35 0.0002 insulin-like growth factor 1 (somatomedin C)
Cell motility (GO:0006928; GO:0030334)
IGF1 −0.35 0.0002 insulin-like growth factor 1 (somatomedin C)
G-protein coupled receptor pathway (GO:0007186)
RASD1 −0.31 0.0009 RAS, dexamethasone-induced 1
Transcription (GO:0006350; GO:0006355; GO:0006357; GO:0006366; GO:0016481; GO:0045449; GO:0045893; GO:0045941)
SOX17 −0.28 0.0026 SRY (sex determining region Y)-box 17
EBF1 −0.33 0.0005 early B-cell factor 1
DNA metabolic process (GO:0006139; GO:0006260; GO:0006310; GO:0015074)
IGF1 −0.35 0.0002 insulin-like growth factor 1 (somatomedin C)
Insulin-like growth factor receptor signaling pathway (GO:0043568)
IGF1 −0.35 0.0002 insulin-like growth factor 1 (somatomedin C)
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Table 3
Non-protein coding (npc) regions overexpressed in the breast of parous postmenopausal women
GeneSymbol Probe ID Log Ratio Gene Names
CXorf50B 242292_at 0.35 non-protein coding RNA 246B
MALAT1 224558_s_at 0.56 metastasis associated lung adenocarcinoma transcript 1
MALAT1 224558_s_at 0.56 metastasis associated lung adenocarcinoma transcript 1
NCRNA00173 237591_at 0.39 non-protein coding RNA 173
NCRNA00201 225786_at 0.47 non-protein coding RNA 201
NEAT1 224565_at 0.38 nuclear paraspeckle assembly transcript 1
NEAT1 224566_at 0.50 nuclear paraspeckle assembly transcript 1
XIST 224589_at 0.39 X (inactive)-specific transcript
XIST 221728_x_at 0.57 X (inactive)-specific transcript
XIST 214218_s_at 0.57 X (inactive)-specific transcript
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